GlassScriptPhysician profile
Matthew L Surgan
NPI 1871798579
$4,163.94
in general payments reported to CMS, 2019-2025
30 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $198 · 2021: $598 · 2022: $784 · 2023: $806 · 2024: $1,013 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,341 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25.00 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,340.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25.00 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,007.36 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $738.78 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $471.02 | 2019-2025 | Synthroid |
| Lilly USA, LLC | $347.91 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $273.16 | 2019-2025 | |
| Amgen INC. | $169.72 | 2019-2023 | Evenity, Prolia |
| Abbott Laboratories | $130.98 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $119.72 | 2022-2025 | |
| Amarin Pharma, INC. | $109.01 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $95.83 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $82.25 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $76.20 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $59.02 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $55.81 | 2024-2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $55.22 | 2021-2024 | Unithroid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bigfoot Biomedical INC | $46.55 | 2022 | |
| Janssen Pharmaceuticals, INC | $42.37 | 2019 | |
| Medtronic, INC. | $36.37 | 2021-2023 | Minimed 780g |
| Ibsa Pharma INC. | $31.91 | 2023-2024 | Tirosint, Tirosint, Licart |
| Xeris Pharmaceuticals, INC. | $27.77 | 2021-2025 | Recorlev |
| Sequel Med Tech, LLC | $27.42 | 2025 | Twiist |
| Becton, Dickinson and Company | $25.00 | 2024 | |
| Acella Pharmaceuticals, LLC | $20.20 | 2025 | NP Thyroid 60 |
| Cequr Corporation | $19.36 | 2022 | |
| Insulet Corporation | $18.38 | 2022 | |
| Neurocrine Biosciences, INC. | $16.57 | 2025 | |
| Recordati_rare_diseases_inc. | $16.29 | 2023 | Signifor Lar, Isturisa |
| Senseonics, Incorporated | $16.00 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.99 | 2020 | |
| Valeritas, INC. | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Surgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.